Anthropic acquires one-person biotech startup using Claude for drug research
The AI company buys a startup that used Claude to coordinate work across 11 labs, marking a deepening push into biotech applications.
Part of a larger narrative
Anthropic's IPO filing reveals $2-for-$1 compute economics, huge spending commitments
- Anthropic warns of imminent recursive self-improvement in AI models
- Anthropic's amended S-1 shows Q3 revenue near $17B, loss widens to $23.3B
- Anthropic's IPO filing reveals $2-for-$1 compute economics, huge spending commitments
- Anthropic acquires one-person biotech startup using Claude for drug researchyou are here
What to know
- Anthropic acquired a one-person biotech startup that had used Claude to manage research coordination across 11 labs.
- The deal reflects Anthropic's strategic expansion into biotech applications and demonstrates practical uses of its AI system in drug development.
Anthropic AI company
How it unfolded 0 developments, newest first · click a bar or a number to jump
-
background
Anthropic acquires one-person biotech startup — Anthropic purchased a small drug startup that had used Claude to coordinate work across 11 laboratories. The acquisition signals the company's deeper push into biotech applications.
What people are saying 24 voices from 3 sites · best of 59 · verbatim
- Oct 28
-
C
Anthropic acquired a one-person biotech startup. Its founder used Claude to coordinate 11 labs and got early results in mice for a potential muscular dystrophy treatment in under 18 months. The company still used 8 consultants but AI shrunk the full-time employees needed down to one person. https://www. rdworldonline.com/anthropic-ac…
-
Largely, most of the paper pushed in these big pharma companies is in regulation and compliance. So much so that it isn't that much of a stretch to say they are mostly regulatory compliance companies with a research division attached. It's not entirely true, of course, but it does fit a bit. Also, there are a lot of regulatory agencies out there…
-
My sense, from working in the biotech industry, is that this is going to take much longer than people think. I have two clients using ML/AI for drug discovery and their results have been mixed. There are cases where a drug was identified by ML but then failed during animal testing.Unfortunately, the feedback cycle in drug development is measured…
-
My wife lives with a rare form of Muscular Dystrophy - GNE Myopathy. It's a progressive muscle wasting disorder, eventually she will be bed ridden. Her parents (prominent biologists themselves) have dedicated last 25 years of their lives trying to find a cure for her through conventional science in vain.If the work by Cody Trangbarger pays off and…
-
I am incredibly optimistic on AI, especially for drug discovery. However, the belief that AI drugs will be more likely to pass phase 2 tests than others is either based on the assumption that AI will mostly be used to attack safe indications (me too drugs for targets that already have therapies operating on the same mechanism), or on some belief…
-
I don't think having the team of PhDs with infinite resources at Anthropic holding the place of drillers in your metaphor holds very well.Eli Lilly might be the experienced horse carriage operator to Anthropic as the Ford motor company here instead. Or Blackberry when the iPhone was announced.The biggest advantage Eli Lilly has is in navigating…
-
I've found, from working with scientists and non-software specialists at NASA, universities, and various industries, that the big wins come from specialists learning to code as the vanguard, then a few engineers taking over for production. I think that's ever more true with AI assistance, and I'm not sure what is left for product-ization. All I…
-
We need to focus on making the stuff we already have cheaper and faster.That's where an LLM and robots can come into play potentially. If we can just scan everyone every year at their physical we could prevent potentially millions of deaths. Yea there are downsides but the downsides are all the extra tests afterwards which we would then have to…
-
Anthropic buys a one-person biotech and starts its own drug programmes https:// thenextweb.com/news/anthropic- mithril-acquisition-claude-drug-development?utm_source=flipboard&utm_medium=activitypub Posted into TNW - All Stories @ tnw-all-stories-thenextweb
-
Drug discovery is a problem thats hard to define and measure. But we know that LLMs excel where there's clear metrics. Anthropic made a big point about speeding up Claude code and claude.ai with Opus 5.5, OpenAI is doing a sprint on Codex this month.So dear AI labs, here's a drug-related challenge for you that might actually help: streamline the…
-
D
Anthropic paid an undisclosed amount to acquire a *1-person* company working on muscular dystrophy, presumably one using their products. Early progress on accelerating drug development with Claude https://www. anthropic.com/research/early-p rogress-drug-development
-
This is a largely agreed upon problem. What isn't clear is why it seems to get sidestepped in discussion so frequently. No one knows how a molecule will interact with human biology. It can't be simulated computationally to generate data (too slow), there isn't a lot of data in the grand scheme of things, so you can't train a model to actually…
-
C
Anthropic shares early progress on drug development with Claude. https://www. anthropic.com/research/early-p rogress-drug-development OpenAI's Codex CLI reaches rust-v0.165.0. https:// github.com/openai/codex/releas es/tag/rust-v0.165.0 Gemini CLI v0.67.0-preview.0 rolls out a new preview build. https:// github.com/google-gemini/gemin…
- Oct 27
-
> like proposing initial designs for new moleculesJames van Geelen Of Citrini research brought up a good point on a podcast this week, that designing the molecules is perhaps 10-20% of the effort in bringing a drug to market. We have more possible drug designs than ever get developed.Whilst AI drugs might be more likely to pass phase 2 tests than…
-
This is really cool, and so far also just seems to be the model of funding science and discovery that the US government and other grant making entities follow thus far. Submit for RFP to do X with Y. At ANL for example it was (and still is in Computing), use our HPC resources to accelerate your research (after of course review and approval of…
-
It's true though. It's not like math or software where you can do it isolation and work things out logically "on paper." I don't think the solution will be "put a bunch of agents on it and let them figure it out." The tools to model and observe what's going on in full detail don't exist. Far from it. You can't really optimize the trial and error…
-
Coming up with candidate drugs is the easiest part of the process. It’s possible that that could be improved a little (not sped up, but suggesting compounds in silico less likely to fail) and possibly have suggestions for scale up, but those are all hard, and the latter is less amenable to being “read” during trains phase.This has been one of the…
-
It helps with bureaucracy and pipeline generation. That's valuable and frees up time and effort for scientists. But it's not generating new ideas or solving problems like in math/engineering.The problem is that biology is like trying to reverse engineer alien technology to understand how it works. Math/engineering is more like building up…
-
This is one application of AI that I’ve been hopeful for. Accelerating research into new medicines and cures to disorders, diseases, and cancers could be a net positive on human lives. Maybe it’ll help bring R&D costs down so that medicines for rare diseases aren’t out of reach for those that are afflicted by them.> If Claude is to significantly…
-
Anthropic just published some genuinely exciting progress on using Claude to accelerate drug development. And we're talking about actual lab results, not just AI-generated predictions. Working with six biotech and pharmaceutical organizations, Claude has already helped researchers achieve some pr...
-
Anthropic is now doing its own drug discovery after acquiring one-person biotech startup Mithril Medicine! With Claude and 11 external labs, its founder took a potential treatment for a rare form of muscular dystrophy from idea to promising results in mice in under 18 months. [image] [embedded post]
-
Holy shit! This is definitely one of the best uses of Claude. Anthropic is putting Claude inside real drug development programs. Real biotech teams and real lab results. The results are wild: - Enveda: Claude reviewed 1,061 pages of manufacturing docs. It caught all 11 issues the humans found an...
-
Definitely an interesting partnership by Anthropic. AI-driven drug discovery taking a huge leap forward. Excited to see Claude pushing the boundaries in the life sciences space!
-
I have a rare disease with no cure. Id love to see how Claude can help with us, but I'm cautious what it can really advance. Murine models still take time, and clinical trials are slow. I would think most biotech companies lose money at these stages.>> If Claude is to significantly increase the rate of new cures, we need to work with many more…